Abstract
Anaemia is a very common complication of chronic kidney disease (CKD) and renal failure. Since the introduction of ESAs (erythropoiesis-stimulating agents) in the clinical practice, the view of anaemia treatment has changed considerably and, currently, thetreatment safety is preferred to complete correction of anaemia.
In addition to ESAs, a wide range of novel agents developed inorder to favourably affect erythropoiesis have recently been tested. They include, in particular, HIF-stabilizers (roxadustat, molidustat,vadadustat, and daprodustat), sotatercept, or GATA2 inhibitors.
The requirements for treatment safety were the reasonfor the conduction of a number of studies with intravenous iron administration. In routine clinical practice, other iron-containingagents have begun to be used that can have more benefits for the patient, such as a phosphate bond.
Some novel agents areadministered in order to increase the biological availability of iron already deposited in the body, e.g. by means of hepcidin inhibition.The aim of this article is to briefly discuss some of these molecules and studies.